Treats acute pain due to minor strains, sprains, and contusions. Sold as Flector, Licart. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Diclofenac Epolamine (sold as Flector, Licart), first approved Jan 31, 2007, with 2 new uses approved and 1 published complete response letter.
| Diclofenac Epolamine | Part D | $117M | +4% | 34,299 |
| Licart | Part D | $7.7M | -2% | 2,334 |
| Flector | Part D | $1.3M | -23% | 529 |
| Jan 31, 2007 | FlectorNDA 21234 · New active ingredient | Ibsa | 15 | Marketed |
| Dec 19, 2018 | LicartNDA 206976 · TYPE 3/4 | Ibsa Inst Bio | 6 | Marketed |
| Letter | Product | Now |
|---|---|---|
| Mar 24, 2017 | Diclofenac epolamineClinical, Nonclinical, Product Quality | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
